Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

[Pathologies of the musculoskeletal system in diabetes mellitus].

Bodet C, Radermecker RP, Philips JC, Rorive M, Benmouna K, Forthomme B, Wang F, Kaux JF.

Rev Med Liege. 2019 Nov;74(11):572-579. French.

PMID:
31729845
2.

[Continuous glucose monitoring in the management of diabetes : state-of-the art and perspectives].

Radermecker RP.

Rev Med Suisse. 2019 Aug 21;15(659):1444-1447. Review. French.

PMID:
31436059
3.

[Contribution of FreeStyle Libre® in the care of diabetic patients : experience at the CHU of Liege].

Gernay MM, Philips JC, Radermecker RP, Paquot N.

Rev Med Liege. 2018 Nov;73(11):562-569. French.

4.

Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors.

Davin L, Marechal P, Lancellotti P, Martinez C, Pierard L, Radermecker R.

Acta Cardiol. 2019 Aug;74(4):277-281. doi: 10.1080/00015385.2018.1507477. Epub 2018 Oct 17.

5.

Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study.

Charleer S, Mathieu C, Nobels F, De Block C, Radermecker RP, Hermans MP, Taes Y, Vercammen C, T'Sjoen G, Crenier L, Fieuws S, Keymeulen B, Gillard P; RESCUE Trial Investigators.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):1224-1232. doi: 10.1210/jc.2017-02498.

6.

Does Oxidative Stress Play a Role in Altered Characteristics of Diabetic Bone? A Systematic Review.

Bacevic M, Brkovic B, Albert A, Rompen E, Radermecker RP, Lambert F.

Calcif Tissue Int. 2017 Dec;101(6):553-563. doi: 10.1007/s00223-017-0327-7. Epub 2017 Oct 24. Review.

PMID:
29063963
7.

[Lipertance® The ASCOT single-pill combination has finally arrived].

Radermecker RP.

Rev Med Liege. 2017 Sep;72(9):416-422. Review. French.

8.

[Contribution of continuous glucose measurement in the management of gestational diabetes : a pilot study].

Franck M, Philips JC, Emonts P, Radermecker RP.

Rev Med Liege. 2017 Jun;72(6):295-300. French.

9.

L’image du mois - Une tumeur cardiaque indéterminée.

Radermecker RP, Renson V, Delvenne P, Tchana-Sato V, Davin L.

Rev Med Liege. 2017 Jan;72(1):4-5. French. No abstract available.

10.

[PERSONALIZED MEDICINE AND EBM: ETHICAL ASPECTS].

Radermecker RP.

Rev Med Liege. 2015 May-Jun;70(5-6):343-6. French.

11.

[Depression and type 2 diabetes: etiopathogenic analysis of a frequent comorbidity].

Luppens D, Piette C, Radermecker RP, Scantamburlo G, Ansseau M, Pitchot W.

Rev Med Liege. 2014 Nov;69(11):611-7. Review. French.

PMID:
25796774
12.

[Concerns about glycated haemoglobin and the limitations of its interpretations].

Sepulchre E, Lutteri L, Cavalier E, Guerci B, Radermecker RP.

Rev Med Liege. 2014 Sep;69(9):497-503. Review. French.

13.

Simultaneous determination of insulin and its analogues in pharmaceutical formulations by micellar electrokinetic chromatography.

Lamalle C, Servais AC, Radermecker RP, Crommen J, Fillet M.

J Pharm Biomed Anal. 2015;111:344-50. doi: 10.1016/j.jpba.2014.12.038. Epub 2014 Dec 31.

14.

[Treatment of dyslipidemia in 2014: European versus American guidelines].

Radermecker RP.

Rev Med Suisse. 2014 Aug 27;10(439):1534-7. French.

PMID:
25272669
15.

[Is there still an actual place for cardiovascular prevention in the elderly? Focus on antiplatelet and lipid lowering agents].

Radermecker RR, Lancellotti P.

Rev Med Liege. 2014 May-Jun;69(5-6):318-22. Review. French.

16.

[European guidelines for the management of diabetes, prediabeties and cardiovascular disease. First part. Management of diabetes and cardiovascular risk factors].

Scheen AJ, Radermecker RP, Philips JC, Rorive M, De Flines J, Paquot N.

Rev Med Liege. 2013 Nov;68(11):585-92. French.

17.

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).

Devroey D, Radermecker RP, Van der Schueren BJ, Torbeyns B, Jaken RJ.

Int J Clin Pract. 2014 Feb;68(2):180-7. doi: 10.1111/ijcp.12315. Epub 2013 Dec 6.

18.

Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.

Radermecker RP, Fayolle C, Brun JF, Bringer J, Renard E.

Diabetes Metab. 2013 May;39(3):258-62. doi: 10.1016/j.diabet.2012.12.004. Epub 2013 Mar 19.

19.

Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: consensus of experts from SFD, EVADIAC and SFE.

Benhamou PY, Catargi B, Delenne B, Guerci B, Hanaire H, Jeandidier N, Leroy R, Meyer L, Penfornis A, Radermecker RP, Renard E, Baillot-Rudoni S, Riveline JP, Schaepelynck P, Sola-Gazagnes A, Sulmont V, Tubiana-Rufi N, Durain D, Mantovani I, Sola-Gazagnes A, Riveline JP; Société Francophone du Diabète; Société Française d'Endocrinologie; EVAluation dans le Diabète des Implants ACtifs Group.

Diabetes Metab. 2012 Jul;38 Suppl 4:S67-83. doi: 10.1016/S1262-3636(12)71538-0. No abstract available.

20.

[Type 1 diabetes: from genetic predisposition to hypothetical environmental triggers].

Phlips JC, Radermecker RP.

Rev Med Liege. 2012 May-Jun;67(5-6):319-25. Review. French.

21.

Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study.

Riveline JP, Schaepelynck P, Chaillous L, Renard E, Sola-Gazagnes A, Penfornis A, Tubiana-Rufi N, Sulmont V, Catargi B, Lukas C, Radermecker RP, Thivolet C, Moreau F, Benhamou PY, Guerci B, Leguerrier AM, Millot L, Sachon C, Charpentier G, Hanaire H; EVADIAC Sensor Study Group.

Diabetes Care. 2012 May;35(5):965-71. doi: 10.2337/dc11-2021. Epub 2012 Mar 28.

22.

[Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].

Scheen AJ, Radermecker RP, Ernest P, Jandrain BJ.

Rev Med Suisse. 2011 Aug 31;7(306):1621-4, 1626-9. French.

23.

Vitamin D and type 2 diabetes mellitus: where do we stand?

Cavalier E, Delanaye P, Souberbielle JC, Radermecker RP.

Diabetes Metab. 2011 Sep;37(4):265-72. doi: 10.1016/j.diabet.2011.01.001. Epub 2011 Feb 22. Review.

24.

Management of blood glucose in patients with stroke.

Radermecker RP, Scheen AJ.

Diabetes Metab. 2010 Oct;36 Suppl 3:S94-9. doi: 10.1016/S1262-3636(10)70474-2. Review.

25.

Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump.

Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E.

Diabetes Metab. 2010 Nov;36(5):409-13. doi: 10.1016/j.diabet.2010.08.001. Epub 2010 Sep 22.

26.

[Therapeutic education and continuous glucose monitoring in insulin-treated diabetic patients].

Thielen V, Radermecker RP, Renard E, Bringer J, Scheen AJ.

Rev Med Suisse. 2010 Sep 1;6(260):1596-600. French.

27.

[How to optimize lipid-lowering therapy: do not forget patient's non-compliance].

Radermecker RP, Scheen AJ.

Rev Med Liege. 2010 May-Jun;65(5-6):311-7. French.

28.

[Strategies avoiding inertia and non compliance in clinical trials].

Jandrain BJ, Ernest P, Radermecker RP, Scheen AJ.

Rev Med Liege. 2010 May-Jun;65(5-6):246-9. French.

29.

Addition of incretin therapy to metformin in type 2 diabetes.

Scheen AJ, Radermecker RP.

Lancet. 2010 Apr 24;375(9724):1410-2. doi: 10.1016/S0140-6736(10)60399-6. No abstract available.

30.

What makes tight glycemic control tight? The impact of variability and nutrition in two clinical studies.

Suhaimi F, Le Compte A, Preiser JC, Shaw GM, Massion P, Radermecker R, Pretty CG, Lin J, Desaive T, Chase JG.

J Diabetes Sci Technol. 2010 Mar 1;4(2):284-98.

31.

[Ezetimibe (Ezetrol) in patients with diabetes].

Scheen AJ, Radermecker RP.

Rev Med Liege. 2009 Dec;64(12):606-11. French.

32.

Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control.

Radermecker RP, Renard E, Scheen AJ.

Diabetes Metab Res Rev. 2009 Sep;25(6):491-501. doi: 10.1002/dmrr.961. Review.

PMID:
19496088
33.

Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa.

Delanaye P, Cavalier E, Radermecker RP, Paquot N, Depas G, Chapelle JP, Scheen AJ, Krzesinski JM.

Clin Nephrol. 2009 May;71(5):482-91.

PMID:
19473607
34.

[Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes].

De Flines J, Radermecker RP, Jandrain BJ, Scheen AJ.

Rev Med Liege. 2009 Feb;64(2):109-14. French.

35.

Continuous glucose monitoring as a tool to identify hyperglycaemia in non-diabetic patients with acute coronary syndromes.

Radermecker RP, Sultan A, Piot C, Remy AS, Avignon A, Renard E.

Diabet Med. 2009 Feb;26(2):167-70. doi: 10.1111/j.1464-5491.2008.02643.x.

36.

[Biphasic insulin aspart (NovoMix 50)].

Radermecker RP, Scheen AJ.

Rev Med Liege. 2008 Nov;63(11):688-92. French.

37.

Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa.

Delanaye P, Cavalier E, Radermecker RP, Paquot N, Depas G, Chapelle JP, Scheen AJ, Krzesinski JM.

Nephron Clin Pract. 2008;110(3):c158-63. doi: 10.1159/000166607. Epub 2008 Oct 27.

38.

[Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials].

Radermecker RP, Philips JC, Jandrain B, Paquot N, Scheen AJ.

Rev Med Liege. 2008 Jul-Aug;63(7-8):511-8. French.

39.

[Statin for the brain: update in 2008].

Scheen AJ, Radermecker RP, Sadzot B.

Rev Med Liege. 2008 May-Jun;63(5-6):287-92. French.

40.

[Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia].

Radermecker RR, Philips JC, Jandrain BJ, Paquot N, Lefèbvre PJ, Scheen AJ.

Rev Med Liege. 2008 May-Jun;63(5-6):280-6. French.

41.

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Scheen AJ, Radermecker RP, Philips JC, Rorive M, De Flines J, Ernest P, Paquot N.

Rev Med Liege. 2007;62 Spec No:40-6. Review. French.

42.

[Drug of the month. Ezetimibe/simvastatin tablet (Inegy)].

Scheen AJ, Radermecker RP.

Rev Med Liege. 2007 Sep;62(9):585-90. French.

43.

[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].

Scheen AJ, Radermecker RP, Philips JC, Paquot N.

Rev Med Suisse. 2007 Aug 29;3(122):1884, 1886-8. Review. French.

44.

[Recent treatment perspectives in lipidology].

Scheen AJ, Radermecker R, De Flines J, Ducobu J.

Rev Med Liege. 2007 May-Jun;62(5-6):324-8. Review. French.

45.

[Recent advances in the management of diabetes mellitus].

Paquot N, Philips JC, Radermecker R, Lefèbvre P.

Rev Med Liege. 2007 May-Jun;62(5-6):317-23. Review. French.

46.

Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.

Radermecker RP, Piérard GE, Scheen AJ.

Am J Clin Dermatol. 2007;8(1):21-8. Review.

PMID:
17298103
47.

Staphylococcus aureus endocarditis in a diabetic woman treated by continuous subcutaneous insulin infusion.

Legrand DA, Radermecker RP, Stassen MP, Soyeur DJ, Radermecker MA, Scheen AJ.

Diabetes Metab. 2007 Feb;33(1):79-81. Epub 2007 Jan 26. No abstract available.

PMID:
17258925
48.

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

Radermecker RP, Scheen AJ.

Diabetes Metab Res Rev. 2007 Jul;23(5):348-55. Review.

49.

Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring: response to De Block et al.

Radermecker RP.

Diabetes Care. 2006 Dec;29(12):2762-3; author reply 2763-4. No abstract available.

50.

[Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapy].

Radermecker RP, Scheen AJ.

Rev Med Suisse. 2006 Aug 23;2(76):1910-5. Review. French.

PMID:
16972541

Supplemental Content

Loading ...
Support Center